Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Gunter Hoglinger, MD, professor of neurology and translational neuroscientist at Ludwig Maximillian's University Munich, provided commentary on a newly initiated phase 3 study assessing AMX0035 (Relyrvio; Amylyx Pharmaceuticals) in patients with progressive supranuclear palsy (PSP). Otherwise known as the ORION trial, Hoglinger discussed what went into trial inclusion, primary end points, and why they believe this therapy, which was approved for patients with amyotrophic lateral sclerosis (ALS) in 2022, could have benefits in PSP.  Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:15 – Underlying mechanisms of progressive supranuclear palsy 3:30 – Similarities and differences between ALS and PSP 5:00 – Overview of ORION study design 7:00 – Neurology News Minute 9:15 – Reasons behind specific trial inclusion 10:35 – Primary end points of the study  12:50 – Significance of a potentially successful trial This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Advisory Committee Downvotes Mesenchymal Stem Cell Approach NurOwn as Potential ALS Therapy FDA Approves HoneyNaps’ Artificial Intelligence Sleep Disorder Diagnosis Software FDA Approves Cipaglucosidase Alfa and Miglustat as First Two-Component Therapy for Pompe Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.